Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Fellow in Pulmonary Medicine, Medicine, University of Pennsylvania 2001 - 2004
  • Medical Resident, Medicine, University of Pennsylvania 1998 - 2001
  • M.D., University of Pennsylvania 1998
• 

  Previous Appointments & Affiliations

  • Associate Professor of Medicine, Medicine, Pulmonary, Allergy, and Critical Care Medicine, Medicine 2016 - 2020
  • Assistant Professor of Medicine, Medicine, Pulmonary, Allergy, and Critical Care Medicine, Medicine 2009 - 2016
  • Medical Instructor in the Department of Medicine, Medicine, Pulmonary, Allergy, and Critical Care Medicine, Medicine 2007 - 2009
  • Instructor, Temporary in the Department of Medicine, Medicine, Pulmonary, Allergy, and Critical Care Medicine, Medicine 2007
• Research
• 

  Selected Grants

  • A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks inpatients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) awarded by Boehringer Ingelheim Pharmaceuticals, Inc. 2023 - 2027
  • A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) awarded by Boehringer Ingelheim Pharmaceuticals, Inc. 2023 - 2027
  • Daewoong A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of DWN12088 in Patients With Idiopathic Pulmonary Fibrosis awarded by Daewoong Pharmaceutical Co., Ltd 2023 - 2027
  • AZ ORIN1001-002 D4325C00001: Phase 1b Double-Blind, Placebo-Controlled, Ascending Dose Trial: ORIN1001 in Subjects with Idiopathic Pulmonary Fibrosis awarded by ORINOVE, Inc 2022 - 2027
  • WA42294 PRM-151: A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE LONG-TERM SAFETY AND EFFICACY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) awarded by Genentech, Inc. 2022 - 2027
  • FGCL-3019-095 Pro00108483 Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF) awarded by Fibrogen, Inc. 2022 - 2026
  • WA42293 PRM-151-303: A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS awarded by Genentech, Inc. 2022 - 2025
  • Novartis VAY736: A subject, investigator, and sponsor blinded randomized placebo controlled multicenter study to investigate VAY736 in patients with idiopathic pulmonary fibrosis awarded by Novartis Pharmaceuticals Corporation 2018 - 2024
  • Evaluate Efficacy and Safety of CC-90001 in Subjects with Idiopathic Pulmonary Fibrosis awarded by Celgene Corporation 2017 - 2024
  • ND-L02-s0201-005 Phase 2 randomized double blind placebo controlled study to evaluate safety, tolerability, biological activity, and PK of ND-L02-s0201 in subjects with IPF awarded by Nitto Denko Corporation 2018 - 2023
  • GLPG1690-CL-304 A Phase 3 randomized double blind parallel group, placebo controlled multicenter study to evaluate efficacy and safety of 2 doses of GLPG1690 in addition to local standard of care awarded by Galapagos NV 2019 - 2023
  • BI 1199.248 INBUILD-ON An open label extension trial of the long term safety of nintedanib in patients with progressive fibrosing interstitial lung disease. awarded by Boehringer Ingelheim Corporation 2019 - 2023
  • Pulmonary Fibrosis Foundation Biomarker and/or Patient Registry Protocols awarded by Regents of the University of Michigan 2015 - 2022
  • Idiopathic Pulmonary Fibrosis Prespective Outcomes (IPF-PRO) Registry awarded by Boehringer Ingelheim Pharmaceuticals, Inc. 2014 - 2022
  • Respivant RVT1601-CC-04 SCENIC: Randomized double blind placebo controlled dose ranging efficacy and safety study with inhaled RVT-1601 for the treatment of persistent cough in patients with IPF awarded by Respivant Sciences, GmbH 2019 - 2020
  • A 52-week, double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of Nintedanib, 150 mg twice daily, in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD) awarded by Boehringer Ingelheim Corporation 2017 - 2020
  • Care Center Network Charter Agreement awarded by Pulmonary Fibrosis Foundation 2016 - 2019
  • A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib co-administered with oral sildenafil, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) awarded by Boehringer Ingelheim Corporation 2016 - 2018
  • Promedior PRM-151 awarded by Promedior, Inc 2016 - 2017
  • CHEST ADVANCED CLINICAL TRAINING PROGRAM-Idiopathic Pulmonary Fibrosis awarded by Chest Foundation 2016
  • Idiopathic Pulmonary Fibrosis Clinical Research Network awarded by National Institutes of Health 2005 - 2014
• 

  External Relationships

  • Boehringer Ingleheim
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Case, Amy Hajari, Anne S. Hellkamp, Megan L. Neely, Shaun Bender, Daniel F. Dilling, Mridu Gulati, David L. Hotchkin, et al. “Associations between Patient-reported Outcomes and Death or Lung Transplant in Idiopathic Pulmonary Fibrosis. Data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry.” Ann Am Thorac Soc 17, no. 6 (June 2020): 699–705. https://doi.org/10.1513/AnnalsATS.201906-437OC.
       Full Text  Link to Item
    • O’Brien, Emily C., Anne S. Hellkamp, Megan L. Neely, Aparna Swaminathan, Shaun Bender, Laurie D. Snyder, Daniel A. Culver, et al. “Disease Severity and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis: A Cross-Sectional Analysis of the IPF-PRO Registry.” Chest 157, no. 5 (May 2020): 1188–98. https://doi.org/10.1016/j.chest.2019.11.042.
       Full Text  Link to Item
    • Anderson, C., C. Tocchi, L. Morrison, and C. Rackley. “A Smart-Phrase to Improve Documentation of Supportive Measures for Idiopathic Pulmonary Fibrosis.” Journal for Nurse Practitioners 16, no. 2 (February 1, 2020): 126–30. https://doi.org/10.1016/j.nurpra.2019.09.008.
       Full Text
    • Todd, Jamie L., Megan L. Neely, Robert Overton, Katey Durham, Mridu Gulati, Howard Huang, Jesse Roman, et al. “Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry.” Respir Res 20, no. 1 (October 22, 2019): 227. https://doi.org/10.1186/s12931-019-1190-z.
       Full Text  Link to Item
    • Snyder, Laurie, Megan L. Neely, Anne S. Hellkamp, Emily O’Brien, Joao de Andrade, Craig S. Conoscenti, Thomas Leonard, et al. “Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry.” Respir Res 20, no. 1 (May 30, 2019): 105. https://doi.org/10.1186/s12931-019-1043-9.
       Full Text  Link to Item
    • Buckley, Lenore, Gordon Guyatt, Howard A. Fink, Michael Cannon, Jennifer Grossman, Karen E. Hansen, Mary Beth Humphrey, et al. “2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.” Arthritis Care Res (Hoboken) 69, no. 8 (August 2017): 1095–1110. https://doi.org/10.1002/acr.23279.
       Full Text  Link to Item
    • Buckley, Lenore, Gordon Guyatt, Howard A. Fink, Michael Cannon, Jennifer Grossman, Karen E. Hansen, Mary Beth Humphrey, et al. “2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.” Arthritis Rheumatol 69, no. 8 (August 2017): 1521–37. https://doi.org/10.1002/art.40137.
       Full Text  Link to Item
    • Blink, Bernt van den, Marlous R. Dillingh, Leo C. Ginns, Lake D. Morrison, Matthijs Moerland, Marlies Wijsenbeek, Elizabeth G. Trehu, Brian J. Bartholmai, and Jacobus Burggraaf. “Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy.” Eur Respir J 47, no. 3 (March 2016): 889–97. https://doi.org/10.1183/13993003.00850-2015.
       Full Text  Link to Item
    • Andrade, Joao de, Marvin Schwarz, Harold R. Collard, Tedryl Gentry-Bumpass, Thomas Colby, David Lynch, Robert J. Kaner, and Robert J. IPFnet Investigators. “The Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet): diagnostic and adjudication processes.” Chest 148, no. 4 (October 2015): 1034–42. https://doi.org/10.1378/chest.14-2889.
       Full Text  Link to Item
    • Foster, Matthew W., Lake D. Morrison, Jamie L. Todd, Laurie D. Snyder, J Will Thompson, Erik J. Soderblom, Kelly Plonk, et al. “Quantitative proteomics of bronchoalveolar lavage fluid in idiopathic pulmonary fibrosis.” J Proteome Res 14, no. 2 (February 6, 2015): 1238–49. https://doi.org/10.1021/pr501149m.
       Full Text  Link to Item
    • Morrison, L. “Interstitial lung disease and autoimmune lung diseases: An issue of the immunology and allergy clinics of North America.” Annals of the American Thoracic Society 11, no. 7 (September 1, 2014): 1168. https://doi.org/10.1513/AnnalsATS.201401-025OT.
       Full Text
    • Swigris, Jeffrey J., David L. Streiner, Kevin K. Brown, Amanda Belkin, Kathy E. Green, Frederick S. Wamboldt, and Frederick S. IPFnet Investigators. “Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.” Respir Med 108, no. 1 (January 2014): 181–88. https://doi.org/10.1016/j.rmed.2013.12.009.
       Full Text  Link to Item
    • Collard, Harold R., Eric Yow, Luca Richeldi, Kevin J. Anstrom, Craig Glazer, and Craig IPFnet investigators. “Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.” Respir Res 14, no. 1 (July 13, 2013): 73. https://doi.org/10.1186/1465-9921-14-73.
       Full Text  Link to Item
    • Raghu, Ganesh, Juergen Behr, Kevin K. Brown, Jim J. Egan, Steven M. Kawut, Kevin R. Flaherty, Fernando J. Martinez, et al. “Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.” Ann Intern Med 158, no. 9 (May 7, 2013): 641–49. https://doi.org/10.7326/0003-4819-158-9-201305070-00003.
       Full Text  Link to Item
    • Meltzer, Eric B., William T. Barry, Thomas A. D’Amico, Robert D. Davis, Shu S. Lin, Mark W. Onaitis, Lake D. Morrison, Thomas A. Sporn, Mark P. Steele, and Paul W. Noble. “Bayesian probit regression model for the diagnosis of pulmonary fibrosis: proof-of-principle.” Bmc Med Genomics 4 (October 5, 2011): 70. https://doi.org/10.1186/1755-8794-4-70.
       Full Text  Link to Item
    • Idiopathic Pulmonary Fibrosis Clinical Research Network, Gary W., David A. Zisman, Marvin Schwarz, Kevin J. Anstrom, Harold R. Collard, Kevin R. Flaherty, and Gary W. Hunninghake. “A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.” N Engl J Med 363, no. 7 (August 12, 2010): 620–28. https://doi.org/10.1056/NEJMoa1002110.
       Full Text  Link to Item
    • Meltzer, E. B., L. D. Morrison, T. A. Sporn, S. M. Palmer, M. P. Steele, and P. W. Noble. “Longitudinal Changes in Pathological Specimens Obtained from Patients with Chronic Fibrotic Interstitial Pneumonia.” American Journal of Respiratory and Critical Care Medicine 179 (January 1, 2009).
       Link to Item
    • Stevens, Paul A., Andrea Pettenazzo, Frank Brasch, Surafel Mulugeta, Aldo Baritussio, Matthias Ochs, Lake Morrison, Scott J. Russo, and Michael F. Beers. “Nonspecific interstitial pneumonia, alveolar proteinosis, and abnormal proprotein trafficking resulting from a spontaneous mutation in the surfactant protein C gene.” Pediatr Res 57, no. 1 (January 2005): 89–98. https://doi.org/10.1203/01.PDR.0000147567.02473.5A.
       Full Text  Link to Item
    • Kim, J. J., J. S. Yang, D. J. Lee, D. M. Wilson, L. K. Nottingham, L. Morrison, A. Tsai, et al. “Macrophage colony-stimulating factor can modulate immune responses and attract dendritic cells in vivo.” Hum Gene Ther 11, no. 2 (January 20, 2000): 305–21. https://doi.org/10.1089/10430340050016049.
       Full Text  Link to Item
    • Agadjanyan, M. G., J. J. Kim, N. Trivedi, D. M. Wilson, B. Monzavi-Karbassi, L. D. Morrison, L. K. Nottingham, et al. “CD86 (B7-2) can function to drive MHC-restricted antigen-specific CTL responses in vivo.” J Immunol 162, no. 6 (March 15, 1999): 3417–27.
       Link to Item
    • Kim, J. J., A. Tsai, L. K. Nottingham, L. Morrison, D. M. Cunning, J. Oh, D. J. Lee, et al. “Intracellular adhesion molecule-1 modulates beta-chemokines and directly costimulates T cells in vivo.” J Clin Invest 103, no. 6 (March 1999): 869–77. https://doi.org/10.1172/JCI6024.
       Full Text  Link to Item
    • Kim, J. J., N. N. Trivedi, D. M. Wilson, S. Mahalingam, L. Morrison, A. Tsai, M. A. Chattergoon, et al. “Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine.” Oncogene 17, no. 24 (December 17, 1998): 3125–35. https://doi.org/10.1038/sj.onc.1201736.
       Full Text  Link to Item
    • Kim, J. J., L. K. Nottingham, D. M. Wilson, M. L. Bagarazzi, A. Tsai, L. D. Morrison, A. Javadian, A. A. Chalian, M. G. Agadjanyan, and D. B. Weiner. “Engineering DNA vaccines via co-delivery of co-stimulatory molecule genes.” Vaccine 16, no. 19 (November 1998): 1828–35. https://doi.org/10.1016/s0264-410x(98)00177-7.
       Full Text  Link to Item
    • Kim, J. J., L. K. Nottingham, J. I. Sin, A. Tsai, L. Morrison, J. Oh, K. Dang, et al. “CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines.” J Clin Invest 102, no. 6 (September 15, 1998): 1112–24. https://doi.org/10.1172/JCI3986.
       Full Text  Link to Item
    • Kim, J. J., H. C. Maguire, L. K. Nottingham, L. D. Morrison, A. Tsai, J. I. Sin, A. A. Chalian, and D. B. Weiner. “Coadministration of IL-12 or IL-10 expression cassettes drives immune responses toward a Th1 phenotype.” J Interferon Cytokine Res 18, no. 7 (July 1998): 537–47. https://doi.org/10.1089/jir.1998.18.537.
       Full Text  Link to Item
    • Kim, J. J., M. G. Agadjanyan, N. Trivedi, D. M. Wilson, L. D. Morrison, M. A. Maldonado, W. V. Williams, and D. B. Weiner. “CD86 confers and directs MHC class I restricted CTL induction.” Faseb Journal 12, no. 5 (March 20, 1998).
    • Kim, J. J., N. N. Trivedi, L. K. Nottingham, L. Morrison, A. Tsai, Y. Hu, S. Mahalingam, et al. “Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens.” Eur J Immunol 28, no. 3 (March 1998): 1089–1103. https://doi.org/10.1002/(SICI)1521-4141(199803)28:03<1089::AID-IMMU1089>3.0.CO;2-L.
       Full Text  Link to Item

  • Conference Papers

    • Cottin, V., T. M. Maher, D. Koschel, L. D. Morrison, B. L. Trzaskoma, T. Haselkorn, K. -. U. Kirchgaessler, and L. H. Lancaster. “Global Safety Analysis Of Pirfenidone In Patients With Idiopathic Pulmonary Fibrosis: Pooled Long-Term Results From Two Real-World Studies.” In American Journal of Respiratory and Critical Care Medicine, Vol. 195. AMER THORACIC SOC, 2017.
       Link to Item
    • Lancaster, L. H., L. D. Morrison, A. Auais, B. L. Trzaskoma, S. L. Limb, B. Polman, and K. R. Flaherty. “Pirfenidone In Patients Aged 80 Years And Older With Idiopathic Pulmonary Fibrosis (ipf): Safety Findings From Pooled Trial Databases.” In American Journal of Respiratory and Critical Care Medicine, Vol. 195. AMER THORACIC SOC, 2017.
       Link to Item
    • Van den Blink, B., J. Burggraaf, L. D. Morrison, L. C. Ginns, M. S. Wijsenbeek, M. Moerland, M. R. Dillingh, and M. Lupher. “A Phase I Study Of Prm-151 In Patients With Idiopathic Pulmonary Fibrosis.” In American Journal of Respiratory and Critical Care Medicine, Vol. 187. AMER THORACIC SOC, 2013.
       Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.